DRUG
"Teriparatide", "Forteo® or Teribon"
To examine the effects of terimaratide less than 6 months in osteoporosis
Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
Status
Unknown
Phase
Phase 2
Enrollment
90
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: 1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. 2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. 3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Oct 10, 2018
Study start
Oct 9, 2018
Primary completion
Oct 8, 2023
Study completion
Oct 8, 2025
Results posted
Not reported
Registry updated
Sep 21, 2021
Outcomes
What the study measures.
Primary outcomes
Bone mineral density
Time frame · Change from Baseline Values at 1 year
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 20 Years
- Maximum age
- 120 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Osteoporotic patients who want to take teriparatide and denosumab Exclusion Criteria: * Patients who are allergic to teriparatide or denosumab Patients who are pregnant or breast-feedin
Study locations
1 registered sites.
Japan. Showing up to 24 locations stored in the fast local snapshot.
Yukio Nakamura
Matsumoto, Nagano, Japan
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Teriparatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Sequential Therapies After Osteoanabolic Treatment
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.